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Abstract
Objective: To assess the variation in price among different brands of anticancer medicines available in hospital
pharmacies at Nepalese cancer hospitals.
Methods: The price of different brands of the same anticancer medicines available in the hospital pharmacies of
two cancer hospitals was assessed. Prices of different dosage forms such as a single tablet, capsule and vial were
calculated. The difference in the maximum and minimum price of the same drug manufactured by different
pharmaceutical industries was determined, and the percentage variation in price was calculated. The prices of
medicines (brands) were also compared with the price determined by the government where available.
Results: Price variation was assessed for 31 anticancer medicines belonging to six broad categories. Prices were
found to vary maximally among the following medicines, each belonging to separate categories: among alkylating
agents, the price of temozolomide 100 mg capsule varied 308%; among antimetabolite agents, the price of
pemetrexed 500 mg injection varied 134%; among hormonal drugs, the price of letrozole 2.5 mg tablet varied
200%; among antibody class, the price of trastuzumab 440 mg injection varied 73%; among natural products, the
price of irinotecan 100 mg injection varied 590%; and among miscellaneous agents, the price of bortezomib 2 mg
injection varied 241%. There was a significant difference in the mean MRP of the alkylating agents with the
antimetabolites (p-value 0.006) and the monoclonal antibody (p-value <.001). Antimetabolites, natural products,
hormonal therapy all had significant mean differences in their MRPs with the monoclonal antibodies. (p-value
<.001) and the monoclonal antibodies had a significant mean difference in the MRP with the miscellaneous agents.
(p-value <.001).
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Conclusions: There was a considerable variation in the price of different brands of anticancer medicines available
in the Nepalese market. The Government of Nepal has regulated the prices of some medicines, including anticancer
medicine. However, it is not enough as prices of the majority of anticancer medicines are still not regulated.
Therefore, further strategies are needed to address the variation in the prices of anticancer medicines available in
the Nepalese market.
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Introduction
Globally, cancer is the second leading cause of death and
is accountable for a probable 9.6 million deaths in the
year 2018 [1]. In a systematic analysis by the Global Bur-
den of Disease Cancer Collaboration in 2016, there were
17.2 million incident cancer cases, 8.9 million deaths,
and 213.2 million Disability-Adjusted Life-Years
(DALYs) due to cancer worldwide [2]. It is one of the
major non-communicable diseases (NCDs) in Nepal [3].
Age-standardized cancer incidence and mortality rates
in Nepal have been estimated to be 103.7 and 77.8 per
100,000 populations respectively in 2018 [4]. Cancer is a
major social and financial burden to Nepalese society
and the healthcare system. Chemotherapy is one of the
common treatment modalities for cancer patients [5].
Anti-cancer medicines are usually expensive [6] and
cause financial distress to the patients, society, and the
country. Studies have reported significant variation in
the prices of the same anti-cancer medicines across dif-
ferent countries (up to 388% variation) [7, 8] and within
a country (up to 714% variation) [9].
Nepal lacks a comprehensive public healthcare finan-
cing system. The government has started a basic Health
Insurance Policy with partial financial coverage in 39
districts of Nepal from April 2016 [10]. This partial sup-
port has various limitations and it is not readily available
to the public [11]. The Government of Nepal (GoN) pro-
vides a partial financial subsidy of Nepalese rupees (NRs)
100,000 (Euro 877.19, USD 925.92) for cancer or other
major health problems requiring tertiary care, which is a
one-off payment. This subsidy covers the price of anti-
cancer medicines and radiotherapy treatment only but
does not cover bed charges, laboratory tests, radiological
examinations, and others treatment cost. It can be
accessed via both the private and government cancer
hospitals [12]. However, this financial support for cancer
patients is inadequate as it covers a very small fraction
of the estimated average treatment cost [13]. The direct
average cost of cancer care in the government hospital
of Nepal was estimated to be NRs 387,000 [Euro
3076.46, USD 3423.23] which are unaffordable to the
Nepalese population [13]. The cost of oncology treat-
ment varies between hospitals with higher costs in pri-
vate hospitals [14]. Therefore, the majority of Nepalese
patients, including cancer patients, rely on out-of-the-
pocket expenditure for the treatments of cancer and
other major health problems [13, 15, 16].
The variation in the price of the same medicines man-
ufactured by different pharmaceutical companies might
have a profound effect on patients’ healthcare expend-
iture, access to treatment and overall treatment out-
come. To address this issue the GoN has published a
notice in the Nepal Gazette in August 2015 regarding
the control of prices of a few common medicines, in-
cluding anticancer medicines [17]. Based on this, the De-
partment of Drug Administration (DDA) controls the
maximum retail price (MRP) of those 117 pharmaceut-
ical products in the Nepalese market [17]. This price
control regulation is effective in controlling the prices of
the limited number of pharmaceutical products available
in the Nepalese market [18], but the inclusion of a lim-
ited number of pharmaceutical products in the price
control list may allow pharmaceutical industries to sell
other products at a higher cost. Previous studies from
Nepal have reported substantial price variation of medi-
cation used for the management and treatment of NCDs
[18–20]. However, these studies did not include antican-
cer medicines. Thus, information on the price, price
variation, and other cost factors of different anticancer
medicines available in the Nepalese market are lacking.
Currently, there are 12 cancer hospitals that provide
diagnostic and treatment services for cancer patients in
Nepal. Of these 12 hospitals, five of them are govern-
ment hospitals. Radiation therapy, chemotherapy, and
surgery are available treatment options in Nepal for can-
cer patients. However, all these services are not available
in all hospitals; only five hospitals (both private and gov-
ernment) out of the 12 cancer hospitals provide compre-
hensive cancer treatment services for different types of
cancers.
There are more than 70 domestic pharmaceutical
companies in Nepal [21] and none currently manufac-
tures anticancer medicines. Nepal has been importing
anticancer medicines mainly from India and Bangladesh
[21]. Study on the prices of different brands of antican-
cer medicines is necessary to find out discrepancies in
the prices of different brands of the same medicines
manufactured by numerous international pharmaceutical
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industries. The findings of this study will provide evi-
dence to prescribers, patients and regulatory bodies to
develop and implement strict policies and strategies
aimed at improving affordability and access to anticancer
medicines. This study aims to assess the variation in
prices of different brands of anticancer medicines avail-




A cross-sectional study was conducted from April 2019
to May 2019. Two private cancer hospitals were purpos-
ively selected for the study, as they were the major spe-
cialized private hospitals for cancer care in Nepal. These
cancer hospitals provide comprehensive treatment in-
cluding, radiation therapy, chemotherapy, and surgery to
the cancer patients. The majority of cancer patients
come to Kathmandu valley for a treatment, which is also
a capital city of Nepal. Both hospitals together cover 25–
35% of cancer patients which is an estimated data ob-
tained from respective hospitals.
Sampling technique
A market basket method, including a total collection of all
available anticancer medicines available at the two selected
hospital pharmacies, was used for sample collection.
Inclusion
Individual anticancer medicine having the same dose
and dosage forms manufactured by ≥2 different pharma-
ceutical companies were included, only medicines actu-
ally available on date April-May 2019.
Exclusion criteria
 Brands with no competitor (i.e., just single brand
available) and formulations containing a
combination of anticancer medicines were excluded.
 Modified-release formulations were not included in
price comparison as modified-release formulations
were not available at both pharmacies.
 We excluded government hospitals in Nepal as
there is a different purchasing system of medicines
in government hospitals.
Data collection
 The research team identified the available anticancer
medicines at two hospitals pharmacies of cancer
hospital by physically checking all the available
medicines.
 MRP i.e. selling prices in NRs were obtained from
the drug dispensing software. Patients usually pay
the exact amount indicated in MRP. It was again
cross-verified by checking the price mentioned in
the labeling.
 The procurement of medicines at both hospitals is a
direct- and competitive-procurement model. Pro-
curement of medicines at private hospitals depends
on lesser cost price or recommendations of doctors
or the availability of drugs. Examining the procure-
ment price of anticancer medicines from the private
hospital of Nepal is difficult.
 In the case of government hospitals, procurement is
mainly based on a tender system. Whatever the
price of procurement is, the MRP of the medicines
doesn’t change.
Data analysis
The price denotes the individual medicines MRP in their
respective labels. The retail price of each unit of the in-
dividual drug with the same strength and dosage form
from all manufacturers were calculated. Price of the oral
anticancer medicine formulation was calculated for a
single tablet or capsule. The price of the injectable medi-
cine was calculated per vial.
The difference in the maximum and minimum price
of the individual drug being manufactured by several
pharmaceutical industries across different brands was
calculated using the following formula: % Price vari-
ation = [Price of the brand with the highest price- price
of the brand with the lowest price] × 100/Price of the
brand with the lowest price.
Anticancer medicines were further categorized into six
different therapeutic class i.e., alkylating agents, anti-
metabolite agents, natural products, hormonal therapy,
monoclonal antibodies, and miscellaneous agents [22] and
price variation was compared within the category. The
MRP indicated in the anticancer medicines label available
at two pharmacies (calculated per unit) was compared
with the Nepalese government fixed price where available
[17]. The available medicines were also compared with the
price set by the government. Data management and ana-
lysis were performed with the help of MS-Excel 2010
(Microsoft Corporation, Redmond, WA, USA) and SPSS
Version 26 (SPSS Inc., Chicago, IL, USA, 2019). Between-
group mean difference in the MRP of the anticancer medi-
cations was performed with a one-way ANOVA test. The
p-value < 0.05 was considered statistically significant.
Results
The variation in the price of 31 anticancer medicines be-
longing to six categories was assessed (Table 1). The
maximum variation was found in irinotecan 100 mg in-
jection (590.30%).
Table 2 shows the maximum price variability (percent-
age) among various categories of anticancer drugs. Out
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Table 1 Price variation among different brands of anticancer medicines available in two private hospital pharmacies of Nepal



















100mg Injection 2 GPNA 11,120.00 12,000.00 7.90 11,560.00 –
Carboplatin 150 mg Injection 8 1393.87 1184.00 1393.60 17.70 1342.60 179.70
450mg Injection 7 4130.77 3476.8 4028.00 15.90 3920.00 472.50
Cisplatin 10mg Injection 5 149.87 100.00 128.00 28.00 113.00 21.20
50mg Injection 6 532.21 512.00 532.20 3.90 520.00 123.50
Cyclophosphamide 1 g Injection 3 GPNA 115.70 204.80 77,00 176.00 –
500mg Injection 2 105.23 101.80 105.20 3.30 105.20 –
200mg Injection 4 GPNA 51.20 80.00 56.30 66.00 110.20
Oxaliplatin 50mg Injection 7 4035.86 3336.50 4035.90 21,00 4000.00 595.90
100mg Injection 7 GPNA 6138.70 7516.60 22.40 7046.70 811.20
Temozolomide 20mg Capsule 3 GPNA 607.70 1232.00 102.70 960.00 –
250mg Capsule 6 GPNA 2550.00 6400.00 151.00 4549.00 3181.00
100mg Capsule 5 GPNA 783.30 3193.80 307.70 2521.80 1430.60
Cytosine Arabinoside
(Cytarabine)
500 mg Injection 2 910.74 807.44 807.55 0 794.10 –
1000mg Injection 2 2068.00 1604.80 2068.00 28.90 2068.00 –
100mg Injection 3 421.23 279.39 421.23 50.80 302.80 –
Capecitabine 500mg Tablet 7 GPNA 188.80 261.00 38.20 212.60 68.80
Gemcitabine 1400mg Injection 2 GPNA 9920.00 13,400.90 35.10 11,660.40 –
1000mg Injection 10 9980.00 7072.00 9980.00 41.10 8626.60 902.60
200mg Injection 8 1706.93 1704.00 1706.90 0.20 1706.90 1.23
Pemetrexed 100mg Injection 5 GPNA 5880.00 11,200.00 90.50 6560.00 4220.00
500mg Injection 8 GPNA 20,512.00 48,000.00 134,00 31,040.00 13,
960.00
Daunorubicin 20mg Injection 2 592.18 592.20 592.20 0 592.17 0
Docetaxel 20 mg Injection 8 GPNA 3144.00 5600.00 78.10 4948.66 848.90
80mg Injection 9 GPNA 7832.00 19,142.10 144.40 17,760.00 4227.90
120mg Injection 3 GPNA 24,464.00 28,342.60 15.90 24,800.00 -
Doxorubicin 10mg Injection 5 328.00 264.00 328.00 24.20 300.8 30.00
50mg Injection 7 1416.28 1280.00 1416.30 10.60 1375.00 121.40
Doxorubicin
(Liposomal)
20 mg Injection 2 GPNA 11,520,00 12,624.00 9.60 12,072.00 –
Epirubicin
Hydrochloride
10mg Injection 4 GPNA 720.00 1184.00 64.40 813.00 349.50
50mg Injection 8 GPNA 3200.00 4400.00 37.50 4082 1621.70
Irinotecan 40mg Injection 4 GPNA 2604.60 14,495.40 456.50 3250.80 8960.30
100mg Injection 5 GPNA 5250.00 36,241.90 590.30 7031.20 16,
395.00
L-Asparaginase 5000 IU Injection 2 1921.38 1504.40 1921.40 27.70 1712.90 –
10,000
IU
Injection 2 GPNA 2330.70 2551.60 9.50 2441.10 –
Paclitaxel 100 mg Injection 7 GPNA 3760.00 7600.00 102.10 6045.80 860.70
260mg Injection 5 GPNA 10,432.00 17,600.00 68.70 15,360.00 4286.20
Vincristine 1 mg Injection 2 89.39 80.50 89.40 11.00 84.90 –
Vinorelbine 10mg Injection 2 GPNA 5065.60 6374.20 25.80 5719.90 –
Anastrozole 1 mg Tablet 5 GPNA 48.80 92.22 89.00 77.60 30.00
Shrestha et al. Journal of Pharmaceutical Policy and Practice            (2020) 13:6 Page 4 of 11
of six categories of anticancer medicines, there were 240
anticancer products with different strengths and dosage
form. Maximum price variability (percentage) was found
in natural products (590.30%). There was variation in
the price of all alkylating agents manufactured by differ-
ent pharmaceutical companies. Within alkylating agents,
temozolomide 100 mg capsule showed the maximum
price variation (307.72%) whereas cyclophosphamide
500 mg injection showed the minimum price variation
(3.33%). With respect to the antimetabolites agents, dif-
ferent brands of cytarabine 500 mg injection and gemci-
tabine 200 mg injection was available with no or
minimal variation in price. However, pemetrexed 500 mg
capsule showed the maximum price variation (134.01%).
Within the natural products category, 590.32% variation
in price was found in irinotecan 100mg injection and
minimum variation was found to be 9.58% in doxorubicin
(liposomal) injection. Among hormonal therapy, three
agents were available whose maximum price variation was
found to be 200% at letrozole 2.5 mg tablet. The minimum
price variation (13.88%) was found in the case of tamoxi-
fen 20mg capsule. Among monoclonal antibody, trastuzu-
mab 440mg injection showed the maximum price
variation of 72.73%. With respect to miscellaneous agents,
a different brand of bortezomib, erlotinib, gefitinib and
imatinib were available. Bortezomib 2mg injection
showed the maximum price variation (240.87%) while
imatinib 400mg capsule showed the minimum price vari-
ation of 43.75%.
Table 3 shows there was a significant difference in the
mean MRP of the different anticancer medicine categor-
ies. Table 3 showed that there was a significant difference
in the mean MRP of the alkylating agents with the antime-
tabolites (p-value 0.006) and the monoclonal antibody (p-
value <.001). Antimetabolites, natural products, hormonal
therapy all had significant mean differences in their MRPs
Table 1 Price variation among different brands of anticancer medicines available in two private hospital pharmacies of Nepal
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Tamoxifen 20mg Capsule 2 4.90 4.30 4.90 13.40 4.61 –
Letrozole 2.5 mg Tablet 3 GPNA 33.30 57.60 73.10 46.00 –
Bevacizumab 100mg Injection 2 GPNA 43,200.00 51,811.70 19.90 47,505.80 –
Ceftuximab 100mg Injection 2 GPNA 31,000.00 32,355.20 4.40 31,677.60 –
Rituximab 500mg Injection 2 GPNA 12,756.80 12,757.20 0 12,757.00 –
100mg Injection 2 GPNA 63,785.60 63,786.20 0 63,785.90 –
Trastuzumab 150mg Injection 2 GPNA 35,915.20 37,683.40 4.90 36,799.30 –
440mg Injection 2 GPNA 97,039.50 99,270.10 2.30 98,154.80 –
Bortezomib 2 mg Injection 5 GPNA 14,400.00 20,640.00 43.30 18,080.00 5640.00
Erlotinib 100 mg Tablet 4 GPNA 533.30 1066.60 100.00 948.00 405.90
150mg Tablet 5 GPNA 634.70 1599.80 152.10 1280.00 762.60
Geftinib 250 mg Tablet 5 GPNA 272 567.40 108.60 368.40 206.40
Imatinib 100 mg Tablet 5 154.74 112.60 154.70 37.40 135.10 36.40
400 mg Capsule 4 474.03 324.30 406.00 25.20 364.80 63.70
GPNA Government price not available, NRs Nepalese rupees, IQR Interquartile Range
Table 2 Price variation among categories of anticancer agents
Category N Median IQR Minimum Maximum Minimum Variation Found Maximum Variation Found
Alkylating agents 65 1920.00 3515.20 51.20 12,000.00 Cyclophosphamide 500mg inj 3.33% Temozolomide 100mg 307.70%
Antimetabolites 48 6480.00 8729.54 187.36 48,000.00 Cytosine Arabinoside
(Cytarabine) 500 mg Inj 0%
Pemetrexed 500mg 134.00%
Natural products 77 5030.00 9017.60 80.48 36,241.92 Doxorubicin (liposomal) inj 9.58% Irinotecan 100mg 590.30%
Hormonal Therapy 10 53.20 44.32 4.32 92.22 Tamoxifen 20 mg capsule 13.88% Letrozole 2.5 mg tablet 200.00%
Monoclonal antibody 12 40,441.69 32,108.32 12,756.80 99,270.12 Rituximab 100, 500 mg inj 0% Trastuzumab 440mg 72.73%.
Miscellaneous agents 28 550.40 1000.51 112.64 20,639.98 Imatinib 400 mg capsule 43.75%. Bortezomib 2 mg injection 240.87%
Total 240
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with the monoclonal antibodies. (p-value <.001) and the
monoclonal antibodies had a significant mean difference
in the MRP with the miscellaneous agents. (p-value
<.001).
Table 4 shows a comparison of the market price of anti-
cancer medicines available in two private hospital pharma-
cies of Nepal with government fixed price. GoN has fixed
the MRP of 45 anticancer medicines (Available in Supple-
mentary File 1). Out of 45 anticancer medicines, 16 anti-
cancer medicines were not available in both the hospital
pharmacies. Ten anti-cancer medicines were available
with only one brand. The MRP of the available brand was
compared with the price fixed by the government. The
negative price variation was found 60.90% in vinblastine
injection 10mg, which is lower than the price set by the
government. Similar negative variation was found in other
anti-cancer medicines, where the available medicines were
below or equal to the price set by the government.
We also observed that all price of 27 anticancer medi-
cines listed in the National list of essential medicines Nepal
(fifth revision) (Available in Supplementary File 2) was reg-
ulated by the DDA. Seven medicines that were listed in the
National list of essential medicines Nepal were not available
in both hospital pharmacies. Nine medicines that are not
listed in the National list of essential medicines Nepal were
not available in both hospital pharmacies.
Discussion
Nepal does not have a clear and transparent medicine pri-
cing policy and even when policy exists for pricing, they are
not implemented strictly. Usually, the cost of pharmaceut-
ical products in Nepal is determined by the pharmaceutical
industries based on their cost of production, marketing cost,
and desired benefit. However, the practices of free pricing
with cost-plus (pricing strategy of determining the selling
price by adding a specific amount markup to that product’s
cost price per unit) and the requirement of displaying the
MRP are applied for all pharmaceutical products. Currently,
the DDA asks international manufacturers’ authorized im-
porters for comparative prices of medicines prior to issuing
the marketing authorization [17] and there is provision for
controlling prices of the drug as per the Drug Act 1978
[23]. However, the implementation has been weaker. Till
now, the DDA has regulated the prices of only 117 pharma-
ceutical products; however, it does not include a large
chunk of medicines that are used for chronic conditions
and specialized diseases such as cancerand stroke [17].
The National list of essential medicines Nepal (fifth re-
vision, first prepared in 1986) 2016 [24, 25], issued by
the GoN has listed 38 anticancer medicines belonging to
different categories of anticancer agents. Many of these
38 anticancer medicines on the National list of essential
medicines Nepal were available in the medicines list that
we investigated. However, seven anticancer medicines
were unavailable which might be due to a regular short-
age of medicines in Nepal [26].
To the best of our knowledge, this is the first study
analyzing price variation among different brands of anti-
cancer medicines available in the selected cancer hospi-
tals of Nepal. This study shows considerable (up to
590.32%) variation in the price of anticancer medicines
in Nepal. However, some brands of anticancer medicines
such as actinomycin D, bleomycin, carboplatin, cisplatin,
and cytosine arabinoside were available even at prices
below the government fixed price which might be due to
price-fixing and market competition. Kolasani et al.
Table 3 Category-wise comparison of MRP of anticancer agents
(I) Category (J) Category Mean Difference (I-J) p-value
Alkylating agents Antimetabolites − 6528.71* 0.006
Natural products − 4397.18 0.102
Hormonal Therapy 2734.06 1.000
Monoclonal antibody −45,661.74* <.001
Miscellaneous agents − 850.56 1.000
Antimetabolites Natural products 2131.52 1.000
Hormonal Therapy 9262.77 0.086
Monoclonal antibody −39,133.03* <.001
Miscellaneous agents 5678.14 0.198
Natural products Hormonal Therapy 7131.24 0.412
Monoclonal antibody −41,264.56* <.001
Miscellaneous agents 3546.62 1.000
Hormonal Therapy Monoclonal antibody −48,395.80* <.001
Miscellaneous agents − 3584.62 1.000
Monoclonal antibody Miscellaneous agents 44,811.18* <.001
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Table 4 Comparison of the market price of anticancer medicines available in two private hospital pharmacies of Nepal with
government fixed price


















3.68 0 NA – – N
2 Actinomycin D injection 0.5 mg 935.44 1 – 934.40 - 0.10 N
3 Alpha Interferon injection 3 miu 1342.08 0 NA – – N
4 Bleomycin injection/
ml
15mg 1088.32 2 946.27 978.56 - 11.20 E
5 Busulphan tablet 2 mg 6.03 0 NA – – N
6 Carboplatin injection 150mg 1393.87 8 1184.00 1393.60 0 E
7 Carboplatin injection 450mg 4130.77 7 3476.80 4028.00 - 2.60 E
8 Chlorambucil tablet 2 mg 79.89 0 NA – – E
9 Cisplatin injection 10mg 149.87 5 100.00 115.20 - 30.10 E
10 Cisplatin injection 50mg 532.21 6 512.00 532.20 0 E
11 Cyclophosphamide tablet 50 mg 6.62 0 NA – – E
12 Cyclophosphamide injection 500mg 105.23 2 101.84 105.23 0 E
13 Cyclosporine capsule 25mg 43.71 0 NA – – E
14 Cyclosporine capsule 50mg 85.25 0 NA – – N
15 Cyclosporine capsule 100 mg 187.78 0 NA – – N
16 Cyclosporine injection 100mg/
ml
209.60 0 NA – – N
17 Cytosine
Arabinoside
injection 100mg 421.23 3 279.39 421.23 0 E
18 Cytosine
Arabinoside
injection 500mg 910.74 2 807.44 807.55 - 12.80 E
19 Cytosine
Arabinoside
injection 1000mg 2068.00 2 1604.80 2068.00 0 N
20 Dacarbazine injection 500mg 1817.98 2 1600.00 1729.00 5.10 E
21 Daunorubicin injection 20mg 592.18 2 592.00 592.17 0 E
22 Doxorubicin injection 10mg 328.00 5 264.00 328.00 0 E
23 Doxorubicin injection 50mg 1416.28 7 1280.00 1416.28 0 E
24 Etoposide capsule 100 mg 92.40 1 – 88.40 - 4.50 E
25 Etoposide injection 100mg/
5 ml
320.27 1 – 300.80 - 6.50 E
26 Flutamide tablet 250 mg 15.22 0 NA – – N
27 Gemcitabine injection 200mg 1706.93 8 1704.00 1706.90 0 N
28 Gemcitabine injection 1000mg 9980.00 10 7072.00 9980.00 0 N
29 Ifosfamide injection 1 g/2 ml 609.26 1 – 609.24 0 E
30 Imatinib tablet 100 mg 154.74 5 112.60 154.70 0 N
31 Imatinib tablet 400 mg 474.03 4 324.30 466.20 - 1.70 N
32 L-Asparaginase injection 500 iu 1921.38 2 1504.41 1703.60 - 12.80 N
33 Melphalan tablet 2 mg 191.73 0 NA – – E
34 Melphalan tablet 5 mg 321.63 0 NA – – E





58.62 1 – 58.62 0 N
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reported high-cost variation with hormonal drugs, fluta-
mide 250 mg tablet i.e. 714.24% and lowest with targeted
drug imatinib mesylate (100 mg; film-coated tablet) i.e.
5.56% [9]. Likewise, Adwal and Baghel’s study reported
high-cost variation with alkylating agent carboplatin 150
mg injection i.e. 1100% and lowest with antimetabolite
anticancer agent cytarabine 500 mg injection 6.56% [27].
Another study by Tadesse and Fang from Ethiopia
shows that the lowest price generic anticancer medicines
were sold 1.29 and 2.62 times the international reference
price in the public and private sectors [28]. A study by
Vogler S et al., where the investigator surveyed the
prices of cancer drugs in high-income countries (16
European countries, Australia, and New Zealand) found
that the price of new cancer drugs varies widely from 28
to 388% [8]. The huge variation in the price of antican-
cer medicines in our study might be due to differences
in the production cost, price control policy not covering
some of the medicines, prescribing by brand name and
pharmaceutical companies influencing the prescriber for
writing their brand using different strategies [29, 30].
The GoN has fixed the MRP of 117 commonly used
medicines, including medicines for chronic diseases and
45 anticancer medicines (with different strengths and dos-
age forms) [31]. This step can help curb down the price of
medicines by decreasing bonuses and other deals and im-
proving access to essential medicines for common people.
On the contrary, price regulation can sometimes inadvert-
ently set medicines price at a level that might not be prof-
itable for the seller and they may withdraw the product
from the market [32]. Such cases have not been reported
in Nepal; however, it provides ground for medicines sellers
to ward off their competitors, especially when regulatory
agencies are weaker due to poor governance and the so-
ciopolitical problem of the Nepalese health system.
In developed countries such as US and Australia, the
cost of anticancer treatment is funded through public and
private health insurance plans along with no or some con-
tribution from self-funding / out-of-pocket payments de-
pending on the type of service received [33–35]. But, in
Nepal, the government provides limited free basic medi-
cines in public health sectors (health posts, primary health
care centers and district hospitals) [19] and limited fund-
ing is available for the treatment of serious health issues
such as cardiac surgery, renal transplant, dialysis, neuro-
surgery, and cancer. The Nepal government provides NRs
100,000 (Euro 877.19, USD 925.92) for cancer treatment
[13]), sickle cell anemia, thalassemia and other life-
threatening diseases [36]. However, the majority of the
treatment cost is to be borne out-of-the-pocket by the fam-
ilies [13, 15, 16, 36]. In this context, huge difference in the
price of same medicine (by a different manufacturer) as
found in this study might affect patients’ expenditure on
medicines, especially when the patient does not know about
variation in prices for different manufacturers or when they
are prescribed with a certain brand that is expensive. Creat-
ing a transparent pricing system and an efficient regulatory
ecosystem might help curb some of the medicines pricing
related issues such as high price variation.
At the national policy level, different strategies such as
cost-plus pricing regulation, external reference pricing,
promotion of generics, and tax exemption policy, are
available to reduce the prices of medicines, including an-
ticancer medicine in developing countries like Nepal [37,
38]. However, at an international level, the recent trend
has been to move away from cost-plus to a value-based
pricing system [39]. The same strategy is used by the
DDA to control the price of 117 pharmaceutical prod-
ucts based on the concept of mean, median and quartile
prices of common brands and external reference pricing
Table 4 Comparison of the market price of anticancer medicines available in two private hospital pharmacies of Nepal with
government fixed price (Continued)














37 Methotrexate tablet 2.5 mg 8.34 1 – 8.33 - 0.10 E
38 Mitomycin C injection 10mg 702.35 1 – 702.35 0 E
39 Oxaliplatin injection 50mg 4035.86 7 3336.50 4035.86 0 N
40 Paclitaxel injection 30mg/5
ml
516.18 0 NA – – N
41 Procarbazine capsule 50mg 55.89 0 NA – – E
42 Tamoxifen capsule 20mg 4.90 2 4.32 4.90 0 E
43 Tamoxifen capsule 10mg 7.68 0 NA – – N
44 Vinblastine injection 10mg 503.31 1 – 312.81 - 60.90 E
45 Vincristine injection 1 mg/ml 89.40 2 80.40 89.40 0 E
GPNA Government price not available, NRs Nepalese rupees, NA Not available, E Listed in National list of essential medicines Nepal (fifth revision), N Not listed in
National list of essential medicines Nepal (fifth revision), −: Negative Price variance
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[31]. Global best practices show that transparent pricing
policies, price strategies based on usage data and better
regulation and monitoring are required to curb down
both high prices and a huge variation in prices of anti-
cancer medicines [38, 40].
At the institutional level, the Drug and Therapeutics
Committee (DTC) of the hospital can play a role in
selecting safe, efficacious and affordable medicines.
However, most of the Nepalese hospitals lack a DTC
and some of them are not functioning properly [26].
The hospitals included in this study have a DTC but due
to lack of proper manpower and lack of time from doc-
tors, DTC was not functioning properly. Both the hospi-
tals in our study did not have hospital formulary that
could have checked and curbed any kind of malpractice
and helped promote the quality use of relatively cost-
effective anticancer medicines. A study by Khatiwoda
et al. reported that medical cost contributed most to the
direct cost, out-of-the-pocket payment was the domin-
ant mechanism and most of the patients faced financial
hardship due to unaffordable medical cost [13]. The
study also reported the financial subsidy to be insuffi-
cient and overall cost (medical, non-medical and direct
cost) to be significantly linked with socioeconomic sta-
tus, age, cancer type, and treatment. A combined ap-
proach including better healthcare financing, resource
allocation based on socioeconomic status and other re-
lated factor and healthcare delivery system that pro-
motes the quality use of anticancer medicines is
required.
Hospital pharmacists can help promote the usage of
appropriate medicines by carrying out cost-effectiveness
and cost-benefit analysis of anticancer medicines [41].
Evidence suggests that clinical pharmacists’ interventions
during cancer therapy can help in the cost-effectiveness
approach and adopt advanced cancer treatment with
optimum and affordable cost [42–44]. The physicians
and patients themselves too can play some role in select-
ing affordable anticancer medicine.
The variation in price may also be reduced if the Nep-
alese domestic pharmaceutical companies manufactured
anticancer medicines. The GoN should develop policies
that promote a tie-up of the Nepalese manufacturing
company with international pharmaceutical companies
so that they can produce some anticancer medicines for
the Nepalese Market. As of now, price fixation up to a
tolerable limit, transparent pricing policy and pricing
based on anticancer medicine usage data would be better
strategies to improve the overall access to anticancer
medicines for Nepalese patients.
Limitations
Some anticancer medicines available in the Nepalese mar-
ket might be missed as this study only compared the price
of different anticancer medicines available at two private
hospital pharmacies of a cancer hospital in Kathmandu
Valley. Both hospitals lack a hospital-based cancer regis-
try, due to this exact proportion of cancer patients in these
two hospitals couldn’t be found out. The government hos-
pitals of Kathmandu valley where most patients get
treated were not included in this study as the hospital
pharmacy is not run by the hospital itself and it was an-
other limitation of this study. Inclusion of all or most of
the anticancer medicines and prices from a government
hospital would have provided a better understanding of
the variation in prices of anticancer medicine and the
findings would have been more generalizable. Non-
inclusion of the different combinations of anticancer med-
icines was another drawback of this study. Procurement
prices of anticancer medicines could not be examined due
to the privacy policy of the procurement committee of the
hospitals. The inclusion of procurement price would have
given an estimate of the average markups by the
pharmacy.
Conclusion
Our study exhibits considerable variation in the price of dif-
ferent brands and among different categories of the anti-
cancer medicines available in the two cancer hospitals of
Nepal. The currently adopted price control policy by the
GoN was found to be effective in reducing the price as well
as the variation in such price of medicine manufactured by
different pharmaceutical companies and, thus, this policy,
should be extended to other medications used for the man-
agement and treatment of NCDs. Generic prescribing
(maintaining the quality, safety, and efficacy), external refer-
ence pricing, tax exemption and stringent assessment of
the implementation of current policies would aid in revers-
ing the augmented pattern of price variation of anticancer
medicines and by providing cost-competitive options, pro-
vide much-needed relief to the patients.
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